Atossa Genetics (NASDAQ:ATOS), Inc. (NASDAQ: ATOS) is a clinical-stage biotechnology company focused on developing novel therapeutics and diagnostics for breast cancer and other breast-related disorders. The company’s mission centers on improving patient outcomes through targeted therapies and minimally invasive diagnostic tools. Atossa’s research and development efforts are primarily directed toward addressing unmet medical needs in early-stage breast cancer prevention and treatment.
The company’s pipeline includes two lead therapeutic candidates: oral endoxifen, a metabolite of tamoxifen designed for extended-release dosing to reduce systemic side effects, and topical fulvestrant, a formulation intended for localized delivery directly to breast tissue. In addition to its therapeutic programs, Atossa has developed a proprietary microcatheter device for intraductal sampling of nipple aspirate fluid, enabling biomarker analysis and risk assessment without the need for invasive surgical biopsies. This diagnostic platform is being evaluated for its potential to facilitate earlier detection of pre-cancerous changes.
Founded in 2009 and headquartered in Seattle, Washington, Atossa has leveraged strategic collaborations with academic centers and contract research organizations to advance its clinical programs. Under the leadership of President and CEO Steven C. Quay, M.D., Ph.D., the company has completed multiple Phase 1 and Phase 2 trials, generating data that support the safety and feasibility of its drug candidates. Atossa’s management team includes professionals with extensive experience in oncology drug development, regulatory affairs and medical diagnostics.
Atossa Genetics serves patients and healthcare providers in the United States and is pursuing opportunities to expand its global footprint through partnerships and licensing agreements. The company continues to explore additional indications for its platform technologies, including potential applications in other hormone-responsive conditions. By integrating therapeutic and diagnostic innovation, Atossa aims to create a holistic approach to breast health management and offer new solutions for early intervention.
